Literature DB >> 16674556

Design and analysis of genetic association studies to finely map a locus identified by linkage analysis: sample size and power calculations.

R L Hanson1, H C Looker, L Ma, Y L Muller, L J Baier, W C Knowler.   

Abstract

Association (e.g. case-control) studies are often used to finely map loci identified by linkage analysis. We investigated the influence of various parameters on power and sample size requirements for such a study. Calculations were performed for various values of a high-risk functional allele (fA), frequency of a marker allele associated with the high risk allele (f1), degree of linkage disquilibrium between functional and marker alleles (D') and trait heritability attributable to the functional locus (h2). The calculations show that if cases and controls are selected from equal but opposite extreme quantiles of a quantitative trait, the primary determinants of power are h2 and the specific quantiles selected. For a dichotomous trait, power also depends on population prevalence. Power is optimal if functional alleles are studied (fA= f1 and D'= 1.0) and can decrease substantially as D' diverges from 1.0 or as f(1) diverges from fA. These analyses suggest that association studies to finely map loci are most powerful if potential functional polymorphisms are identified a priori or if markers are typed to maximize haplotypic diversity. In the absence of such information, expected minimum power at a given location for a given sample size can be calculated by specifying a range of potential frequencies for fA (e.g. 0.1-0.9) and determining power for all markers within the region with specification of the expected D' between the markers and the functional locus. This method is illustrated for a fine-mapping project with 662 single nucleotide polymorphisms in 24 Mb. Regions differed by marker density and allele frequencies. Thus, in some, power was near its theoretical maximum and little additional information is expected from additional markers, while in others, additional markers appear to be necessary. These methods may be useful in the analysis and interpretation of fine-mapping studies.

Mesh:

Substances:

Year:  2006        PMID: 16674556     DOI: 10.1111/j.1529-8817.2005.00230.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  5 in total

1.  Variants in ASK1 are associated with skeletal muscle ASK1 expression, in vivo insulin resistance, and type 2 diabetes in Pima Indians.

Authors:  Li Bian; Robert L Hanson; Victoria Ossowski; Kim Wiedrich; Clinton C Mason; Michael Traurig; Yunhua L Muller; Sayuko Kobes; William C Knowler; Leslie J Baier; Clifton Bogardus
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

2.  Protein tyrosine phosphatase 1B is not a major susceptibility gene for type 2 diabetes mellitus or obesity among Pima Indians.

Authors:  M Traurig; R L Hanson; S Kobes; C Bogardus; L J Baier
Journal:  Diabetologia       Date:  2007-02-27       Impact factor: 10.122

3.  Association of variants in the carnosine peptidase 1 gene (CNDP1) with diabetic nephropathy in American Indians.

Authors:  Harini A Chakkera; Robert L Hanson; Sayuko Kobes; Meredith P Millis; Robert G Nelson; William C Knowler; Johanna K Distefano
Journal:  Mol Genet Metab       Date:  2011-02-19       Impact factor: 4.797

4.  Identification of genetic variation that determines human trehalase activity and its association with type 2 diabetes.

Authors:  Yunhua L Muller; Robert L Hanson; William C Knowler; Jamie Fleming; Jayita Goswami; Ke Huang; Michael Traurig; Jeff Sutherland; Chris Wiedrich; Kim Wiedrich; Darin Mahkee; Vicky Ossowski; Sayuko Kobes; Clifton Bogardus; Leslie J Baier
Journal:  Hum Genet       Date:  2013-03-07       Impact factor: 4.132

5.  Strong parent-of-origin effects in the association of KCNQ1 variants with type 2 diabetes in American Indians.

Authors:  Robert L Hanson; Tingwei Guo; Yunhua L Muller; Jamie Fleming; William C Knowler; Sayuko Kobes; Clifton Bogardus; Leslie J Baier
Journal:  Diabetes       Date:  2013-04-29       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.